InvestorsHub Logo
Followers 822
Posts 163181
Boards Moderated 6
Alias Born 09/23/2009

Re: None

Friday, 12/14/2018 10:08:19 AM

Friday, December 14, 2018 10:08:19 AM

Post# of 8370
Love these results from yesterday, steady stream of positive news here for $ETST

Earth Science Tech, Inc. (ETST) Reports Positive Results from Hygee™ Pre-launch Testing






Email Print Friendly Share
December 13, 2018 08:00 ET | Source: Earth Science Tech, Inc.


DORAL, Florida, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces successful in vitro analyses of gynecological samples collected using its new Hygee™ medical device.
Hygee™ is a discreet, wearable medical device that enables a woman to anonymously test for sexually transmitted infections (STIs). As previously announced, samples collected by the Hygee™ device are tested by Procréa. In pre-launch testing at the labs, molecular diagnostic assays successfully identified the presence of Chlamydia in test subjects, confirming earlier testing results in a cohort of more than 500 women.
ETST’s President, Director and Chairman Nickolas S. Tabraue states, “We are pleased to announce positive testing in the pre-launch phase of Hygee™, and would like to thank our carefully selected partners, Procréa, for a job well done. They are a part of the guarantee of our success.”
ETST is on track to launch Hygee™ in early 2019. The Company plans to market the product through its established distribution channels, mentioned in November, thanks to Dermagate’s ISO 13485:2013 certification.
“Hygee™ is an incredible innovation, and we have partners from many countries waiting to market the device,” stated ETST CEO and Chief Scientific Officer Dr. Michel Aubé. “This is only the beginning of realizing the potential of this unique device, and we look forward to updating our shareholders on our progress.”
In its first iteration, Hygee™ will be marketed as an at-home test for chlamydia; however, R&D efforts currently underway indicate that Hygee™ will soon be certified for gonorrhea testing as well.
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ETST News